H.C. Wainwright downgraded Lipocine (LPCN) to Neutral from Buy without a price target after LPCN 1154 did not meet the efficacy endpoint in the Phase 3 trial. The firm cites uncertainty of Lipocine’s development going forward for the downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
- Lipocine weighs path after LPCN 1154 Phase 3 miss
- Lipocine Updates Investor Presentation to Refine Market Messaging
- Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial
- Lipocine price target raised to $11 from $6.75 at Alliance Global
- Lipocine Files Prospectus to Enable $50M Stock Offering